Skip to main content
SpringerLink
Log in

Therapeutic Strategies in Alcohol and Tobacco Addiction

The Psychology of Motivation and Change in Addiction: From Neuroscience to Clinical Practice

  • Chapter
  • First Online:
Book cover Alcohol and Tobacco

  • 603 Accesses

Abstract

Additions define neurobehavioral disorders in which the brain circuits responsible for pleasure, motivation, stress and decision-making are structurally and functionally disturbed. In this section we will talk about how people become addicted and how the activation of the reward system of the brain by alcohol and drugs not only generates rewarding sensations associated with these substances, but also triggers changes in the way a person responds to associated stimuli.

The psychological therapies traditionally used in the treatment of addictions, namely motivational, cognitive and behavioural therapies, are also founded on the same principles of learning and motivational reward systems of the brain that are involved in the aetiopathogenesis of additions. Hence, in the following parts, we will focus on the psychological management of motivation in clinical practice. We talked about how people move along different mental states of change, from absolute denial to acceptance, and how therapists should deal with different stages of motivation to change, and also according to the different settings of clinical intervention.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Agabio R, Trogu E, Pani PP. Antidepressants for the treatment of people with co-occurring depression and alcohol dependence. Cochrane Database Syst Rev. 2018;4:CD008581. https://doi.org/10.1002/14651858.CD008581.

    Article  PubMed  Google Scholar 

  • Ait-Daoud N, Lynch WJ, Penberthy JK, Breland AB, Marzani-Nissen GR, Johnson BA. Treating smoking dependence in depressed alcoholics. Alcohol Res Health. 2006;29(3):213–20.

    PubMed  PubMed Central  Google Scholar 

  • Alaux-Cantin S, Buttolo R, Houchi H, Jeanblanc J, Naassila M. Memantine reduces alcohol drinking but not relapse in alcohol-dependent rats. Addict Biol. 2015;20(5):890–901. https://doi.org/10.1111/adb.12177.

    Article  CAS  PubMed  Google Scholar 

  • Alkam T, Mamiya T, Kimura N, Yoshida A, Kihara D, Tsunoda Y, Aoyama Y, Hiramatsu M, Kim HC, Nabeshima T. Prenatalnicotineexposure decreases the release of dopamine in the medial frontal cortex and induces atomoxetine-responsive neurobehavioral deficits in mice. Psychopharmacology. 2017;234(12):1853–69. https://doi.org/10.1007/s00213-017-4591-z.

    Article  CAS  PubMed  Google Scholar 

  • Ameisen O. Das Ende meiner Sucht. München: Kustmann Verlag; 2008.

    Google Scholar 

  • Anthenelli RM, Smith TL, Craig CE, Tabakoff B, Schuckit MA. Platelet monoamine oxidase activity levels in subgroups of alcoholics: diagnostic, temporal, and clinical correlates. Biol Psychiatry. 1995;38:361–8.

    Article  CAS  PubMed  Google Scholar 

  • Anthenelli R. Smoking cessation in smokers motivated to quit. Presented at American College of Cardiology Scientific Sessions, March 7–10, 2004; New Orleans, LA; 2004.

    Google Scholar 

  • Anthenelli RM, Benowitz NL, West R, St Aubin L, McRae T, Lawrence D, Ascher J, Russ C, Krishen A, Evins AE. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet. 2016;387(10037):2507–20.

    Article  CAS  PubMed  Google Scholar 

  • Anton RF, O’Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, Gastfriend DR, Hosking JD, Johnson BA, LoCastro JS, Longabaugh R, Mason BJ, Mattson ME, Miller WR, Pettinati HM, Randall CL, Swift R, Weiss RD, Williams LD, Zweben A, COMBINE Study Research Group. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006;295(17):2003–17.

    Article  CAS  PubMed  Google Scholar 

  • Aubin HJ, Luquiens A, Berlin I. Pharmacotherapy for smoking cessation: pharmacological principles and clinical practice. Br J Clin Pharmacol. 2014;77:324–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Balla A, Dong B, Shilpa BM, Vemuri K, Makriyannis A, Pandey SC, Sershen H, Suckow RF, Vinod KY. Cannabinoid-1 receptor neutral antagonist reduces binge-like alcohol consumption and alcohol-induced accumbal dopaminergic signaling. Neuropharmacology. 2018;131:200–8. https://doi.org/10.1016/j.neuropharm.2017.10.040.

    Article  CAS  PubMed  Google Scholar 

  • Benkelfat C, Murphy D, Hill J, George DT, Nutt D, Linnoila M. Ethanol like properties of the serotonergic partial agonist m-chlorophenylpiperazine in chronic alcoholic patients. Arch Gen Psychiatry. 1991;48:383.

    Article  CAS  PubMed  Google Scholar 

  • Benowitz NL, Porchet H, Sheiner L, Jacob P III. Nicotine absorption and cardiovascular effects with smokeless tobacco use: comparison with cigarettes and nicotine gum. Clin Pharmacol Ther. 1988;44:23–8.

    Article  CAS  PubMed  Google Scholar 

  • Beresford TP, Arciniegas DB, Alfers J, Clapp L, Martin B, Du Y, Liu D, Shen D, Davatzikos C. Hippocampus volume loss due to chronic heavy drinking. Alcohol Clin Exp Res. 2006a;30(11):1866–70.

    Article  PubMed  Google Scholar 

  • Beresford TP, Arciniegas DB, Alfers J, Clapp L, Martin B, Beresford HF, Du Y, Liu D, Shen D, Davatzikos C, Laudenslager ML. Hypercortisolism in alcohol dependence and its relation to hippocampal volume loss. J Stud Alcohol. 2006b;67(6):861–7.

    Article  PubMed  Google Scholar 

  • Berger IK, Miller SD. Kurzzeittherapie bei Alkoholproblemen. Ein lösungsorientierter Ansatz (engl.: Working with the problem drinker). 2006.

    Google Scholar 

  • Besson J, Aeby F, Kasas A, Lehert P, Potgieter A. Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study. Alcohol Clin Exp Res. 1998;22(3):573–9.

    Article  CAS  PubMed  Google Scholar 

  • Bekiroglu K, Russell MA, Lagoa CM, Lanza ST, Piper ME. Evaluating the effect of smoking cessation treatment on a complex dynamical system. Drug Alcohol Depend. 2017;180:215–22.

    Article  PubMed  PubMed Central  Google Scholar 

  • Blanc M, Daeppen JB. Does disulfiram still have a role in alcoholism treatment? Rev Med Suisse. 2005;1(26):1728–33.

    CAS  PubMed  Google Scholar 

  • Bolt DM, Piper ME, Theobald WE, Baker TB. Why two smoking cessation agents work better than one: role of craving suppression. J Consult Clin Psychol. 2012;80:54–65.

    Article  PubMed  Google Scholar 

  • Bonte W. Begleitstoffe alkoholischer Getränke. Lübeck: Verlag Max Schmidt-Römhild; 1987.

    Google Scholar 

  • Bonnet U, Taazimi B, Borda T, Grabbe HD. Improvement of a woman's alcohol-related dementia via off-label memantine treatment: a 16-month clinical observation. Ann Pharmacother. 2014;48(10):1371–5. https://doi.org/10.1177/1060028014542270.

    Article  PubMed  Google Scholar 

  • Brady KT, Myrick H, Henderson S, Coffey SF. The use of divalproex in alcohol relapse prevention: a pilot study. Drug Alcohol Depend. 2002;67(3):323–30.

    Article  CAS  PubMed  Google Scholar 

  • Brasser SM, Castro N, Feretic B. Alcohol sensory processing and its relevance for ingestion. Physiol Behav. 2015;148:65–70.

    Article  CAS  PubMed  Google Scholar 

  • Van den Brink W, Sorensen P, Torup L, Mann K, Gual A, Group S.S. Long-term efficacy, tolerability and safety of nalmefene as- needed in patients with alcohol dependence: a 1 year, randomized controlled study. J Psychopharmacol. 2014;28:733–44.

    Article  PubMed  CAS  Google Scholar 

  • van den Brink W, Addolorato G, Aubin HJ, Benyamina A, Caputo F, Dematteis M, Gual A, Lesch OM, Mann K, Maremanni I, Nutt D, Paille F, Perney P, Rehm J, Reynaud M, Simon S, Söderpal B, Sommer WH, Walter H, Spanagl R. Efficacy and Safety od Sodium Oxybate in alcohol-dependent patients with a very high drinking risk level. Addict. Biol. 2018;23(4):969–86. Review.

    Google Scholar 

  • van den Brinck W, Sorensen P, Torup L, Mann K, Gual A, Group SS. Long-term efficacy,tolerability and safety of nalmefene as-needed in patients with alcohol dependence: a 1-year, randomized controlled study. J Psychopharmacol. 2014;28:733–44.

    Article  CAS  Google Scholar 

  • Brody AL, Mandelkern MA, London ED, Olmstead RE, Farahi J, Scheibal D, Jou J, Allen V, Tiongson E, Chefer SI, Koren AO, Mukhin AG. Cigarette smoking saturates brain alpha 4 beta 2 nicotinic acetylcholine receptors. Arch Gen Psychiatry. 2006;63(8):907–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Buchhalter AR, Fant RV, Henningfield JE. Novel pharmacological approaches for treating tobacco dependence and withdrawal: current status. Drugs. 2008;68(8):1067–88. Review

    Article  CAS  PubMed  Google Scholar 

  • Buydens-Branchey L, Branchey MH, Noumair D, Lieber CS. Age of alcoholism onset. II: relationship to susceptibility to serotonin precursor availability. Arch Gen Psychiatry. 1989;46:231–6.

    Article  CAS  PubMed  Google Scholar 

  • Cahill K, Ussher M. Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation. Cochrane Database Syst Rev. 2007;(3):CD005353.

    Google Scholar 

  • Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation (review). Cochrane Libr. 2007;1:1–25.

    Google Scholar 

  • Capurso NA. Naltrexone for the treatment of comorbid tobacco and pornography addiction. Am J Addict. 2017;26(2):115–7. https://doi.org/10.1111/ajad.12501.

    Article  PubMed  Google Scholar 

  • Caputo F, Del Re A, Brambilla R, Grignaschi A, Vignoli T, Vigna-Taglianti F, Addolorato G, Zoli G, Cibin M, Bernardi M. Sodium Oxybate in maintaining alcohol abstinence in alcohol abstinence in alcoholic patients according to Lesch Typology a pilot study. J Psychopharmacol. 2014a;28(1):23–30.

    Article  PubMed  CAS  Google Scholar 

  • Caputo F, Skala K, Mirijello A, Ferrulli A, Walter H, Lesch O, Addolorato G. Sodium Oxybate in the treatment of alcohol withdrawal syndrome: a randomized double—blind comparative study versus oxacepam. The GATE 1 trial. CNS Drugs. 2014b;28(8):743–52.

    Article  CAS  PubMed  Google Scholar 

  • Caputo F, Vignoli T, Maremmani I, Bernardi M, Zoli G. Gamma hydroxibutyric acid (GHB ) for the treatment of alcohol dependence: a review. Int J Environ Res Public Health. 2009;6(6):1917–29.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Caputo F, Addolorato G, Trevisani F, Bernardi M. Gamma-hydroxybutyrate as a treatment for alcoholism. Lancet. 2005;366(9490):981–2.

    Article  PubMed  Google Scholar 

  • Caputo F, Addolorato G, Lorenzini F, Domenicali M, Greco G, del RE A, Gasbarrini G, Stefanini GF, Bernardi M. Gamma-hydroxybutyric acid versus naltrexone in maintaining alcohol abstinence: an open randomized comparative study. Drug Alcohol Depend. 2003;70(1):85–91.

    Article  CAS  PubMed  Google Scholar 

  • Cardoso RA, Brozowski SJ, Chavez-Noriega LE, Harpold M, Valenzuela CF, Harris RA. Effects of ethanol on recombinant human neuronal nicotinic acetylcholine receptors expressed in Xenopus oocytes. J Pharmacol Exp Ther. 1999;289(2):774–80.

    CAS  PubMed  Google Scholar 

  • Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, McClay J, Mill J, Martin J, Braithwaite A, Poulton R. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science. 2003;301(5631):386–9.

    Article  CAS  PubMed  Google Scholar 

  • Caspi A, Moffitt TE. Gene-environment interactions in psychiatry: joining forces with neuroscience. Nat Rev Neurosci. 2006;7(7):583–90.

    Article  CAS  PubMed  Google Scholar 

  • Cheer JF, Wassum KM, Sombers LA, Heien ML, Ariansen JL, Aragona BJ, Phillips PE, Wightman RM. Phasic dopamine release evoked by abused substances requires cannabinoid receptor activation. J Neurosci. 2007;27(4):791–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Chick J. Acamprosate as an aid in the treatment of alcoholism. Alcohol Alcohol. 1995;30(6):785–7.

    CAS  PubMed  Google Scholar 

  • Chick J, Anton R, Checinski K, Croop R, Drummond DC, Farmer R, Labriola D, Marshall J, Moncrieff J, Morgan MY, Peters T, Ritson B. A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol Alcohol. 2000;35(6):587–93.

    Article  CAS  PubMed  Google Scholar 

  • Chick J. Disulfiram: cautions on liver function; how to supervise. Addiction. 2004;99(/1):25.

    Article  PubMed  Google Scholar 

  • Choi K, Sabado M, El-Toukhy S, Vogtmann E, Freedman ND, Hatsukami D. Tobacco product use patterns, and nicotine and tobacco-specific nitrosamine exposure: NHANES 1999–2012. Cancer Epidemiol Biomark Prev. 2017;26(10):1525–30. https://doi.org/10.1158/1055-9965.EPI-17-0338.

    Article  CAS  Google Scholar 

  • Cloninger CR, Sigvardsson S, Gilligan SB, von Knorring AL, Reich T, Bohman M. Genetic heterogeneity and the classification of alcoholism. Adv Alcohol Subst Abuse. 1988;7(3–4):3–16.

    Article  CAS  PubMed  Google Scholar 

  • Coe JW, Brooks PR, Vetelino MG, Wirtz MC, Arnold EP, Huang J, Sands SB, Davis TI, Lebel LA, Fox CB, Shrikhande A, Heym JH, Schaeffer E, Rollema H, Lu Y, Mansbach RS, Chambers LK, Rovetti CC, Schulz DW, Tingley FD 3rd, O’Neill BT. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem. 2005;48(10):3474–7.

    Article  CAS  PubMed  Google Scholar 

  • Cohen C, Perrault G, Voltz C, Steinberg R, Soubrie P. SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. Behav Pharmacol. 2002;13:451–63.

    Article  CAS  PubMed  Google Scholar 

  • Cohen C, Kodas E, Griebel G. CB1 receptor antagonists for the treatment of nicotine addiction. Pharmacol Biochem Behav. 2005;81(2):387–95.

    Article  CAS  PubMed  Google Scholar 

  • Colombo G, Agabio R, Fa M, Guano L, Lobina C, Loche A, Reali R, Gessa GL. Reduction of voluntary ethanol intake in ethanol-preferring sP rats by the cannabinoid antagonist SR-141716. Alcohol Alcohol. 1998;33(2):126–30.

    Article  CAS  PubMed  Google Scholar 

  • Colombo G, Serra S, Vacca G, Carai MA, Gessa GL. Endocannabinoid system and alcohol addiction: pharmacological studies. Pharmacol Biochem Behav. 2005;81(2):369–80.

    Article  CAS  PubMed  Google Scholar 

  • Colombo G, Orrù A, Lai P, Cabras C, Maccioni P, Rubio M, Gessa GL, Carai MA. The cannabinoid CB1 receptor antagonist, rimonabant, as a promising pharmacotherapy for alcohol dependence: preclinical evidence. Mol Neurobiol. 2007;36(1):102–12.

    Article  CAS  PubMed  Google Scholar 

  • Cooper ML, Frone M, Russell M, Mudar P. Drinking to regulate positive and negative emotions: a motivational model of alcohol use. J Pers Soc Psychol. 1995;69:990–1005.

    Article  CAS  PubMed  Google Scholar 

  • Cornelius JR, Salloum IM, Mezzich J, Cornelius MD, Fabrega H, Ehler JG, Ulrich RF, Thase ME, Mann JJ. Disproportionate suicidality in patients with comorbid major depression and alcoholism. Am J Psychiatr. 1995;152:358–64.

    Article  CAS  PubMed  Google Scholar 

  • Covey LS, Glassman AH, Jiang H, Fried J, Masmela J, Loduca C, Petkova E, Rodriguez K. A randomized trial of bupropion and/or nicotine gum as maintenance treatment for preventing smoking relapse. Addiction. 2007;102(8):1292–302.

    Article  PubMed  Google Scholar 

  • Coyle JT. Substance use disorders and schizophrenia: a question of shared glutamatergic mechanisms. Neurotox Res. 2006;10(3–4):221–33.

    Article  CAS  PubMed  Google Scholar 

  • Crews FT, Collins MA, Dlugos C, Littleton J, Wilkins L, Neafsey EJ, Pentney R, Snell LD, Tabakoff B, Zou J, Noronha A. Alcohol-induced neurodegeneration: when, where and why? Alcohol Clin Exp Res. 2004;28(2):350–64.

    Article  PubMed  Google Scholar 

  • Danysz W, Parsons CG, Jirgensons A, Kauss V, Tillner J. Amino-alkyl-cyclohexanes as a novel class of uncompetitive NMDA receptor antagonists. Curr Pharm Des. 2002;8(10):835–43.

    Article  CAS  PubMed  Google Scholar 

  • Deehan GA Jr, Knight CP, Waeiss RA, Engleman EA, Toalston JE, McBride WJ, Hauser SR, Rodd ZA. Peripheral administration of ethanol results in a correlated increase in dopamine and serotonin within the posterior ventral tegmental area. Alcohol Alcohol. 2016;51(5):535–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • De Sousa A, De Sousa A. A one-year pragmatic trial of naltrexone vs disulfiram in the treatment of alcohol dependence. Alcohol Alcohol. 2004;39(/6):528–31.

    Article  PubMed  Google Scholar 

  • De Witte P, Littleton J, Parot P, Koob G. Neuroprotective and abstinence-promoting effects of acamprosate: elucidating the mechanism of action. CNS Drugs. 2005;19(/6):517–37.

    Article  PubMed  Google Scholar 

  • Demir B, Ucar G, Ulug B, Ulusoy S, Sevinc I, Batur S. Platelet monoamine oxidase acitivity in alcoholism subtypes: relationships to personality and executive functions. Alcohol Alcohol. 2002;37:597–602.

    Article  CAS  PubMed  Google Scholar 

  • Després JP, Golay A, Sjöström L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med. 2005;353:2121–34.

    Article  PubMed  Google Scholar 

  • DHS (Deutsche Hauptstelle für Suchtfragen). Alkoholabhängigkeit. Suchtmedizinische Reihe, 4.Auflage. 2013a

    Google Scholar 

  • DHS (Deutsche Hauptstelle für Suchtfragen. Tabakabhängigkeit. Suchtmedizinische Reihe, 4.Auflage. 2013b

    Google Scholar 

  • Donoghue K, Elzerbi C, Saunders R, Whittington C, Pilling S, Drummond C. The efficacy of accamprosate and naltrexone in the treatment of alcohol dependence, Europe versus the rest of the world: a meta-analysis. Addiction. 2015;110:920–30.

    Article  PubMed  Google Scholar 

  • Ebbert JO, Hughes JR, West RJ, Rennard SI, Russ C, McRae TD, Treadow J, Yu CR, Dutro MP, Park PW. Effect of varenicline on smoking cessation through smoking reduction: a randomized clinical trial. JAMA. 2015;313(7):687–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Edwards NB, Simmons RC, Rosenthal TL, Hoon PW, Downs JM. Doxepin in the treatment of nicotine withdrawal. Psychom Theory. 1988;29:203–6.

    CAS  Google Scholar 

  • Evans SM, Levin FR, Brooks DJ, Garawi F. A pilot double-blind treatment trial of memantine for alcohol dependence. Alcohol Clin Exp Res. 2007;31(5):775–82.

    Article  CAS  PubMed  Google Scholar 

  • Etter JF. Cytisine for smoking cessation: a literature review and a meta-analysis. Arch Intern Med. 2006;166(15):1553–9.

    Article  CAS  PubMed  Google Scholar 

  • Featherstone RE, Siegel SJ. The role of nicotine in schizophrenia. Int Rev Neurobiol. 2015;124:23–78. https://doi.org/10.1016/bs.irn.2015.07.002.

    Article  CAS  PubMed  Google Scholar 

  • Ferry LH. Non-nicotine pharmacotherapy for smoking cessation. Prim Care. 1999;26:653–69.

    Article  CAS  PubMed  Google Scholar 

  • Fiore M, Bailey WC, Cohen SJ, Dorfman SF, Goldstein MG, Gritz ER, Heyman RB, Jaen CR, Kottke TE, Lando HA, Mecklenberg RE, Mullen PD, Nett LM, Robinson L, Stizer ML, Tommasello AC, Villejo L, Wewers ME. Treating tobacco use and dependence. Clinical practice guideline. Rockville, MD: US Department of Health and Human Services, Public Health Service; 2000.

    Google Scholar 

  • Fiore MC, Jaen CR, Baker TB. et al. Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. Rockville, MD: US Dept of Health and Humann Services, Public Health Service. 2008.

    Google Scholar 

  • Freeman TP, Das RK, Kamboj SK, Curran HV. Dopamine, urges to smoke, and the relative salience of drug versus non-drug reward. Soc Cogn Affect Neurosci. 2015;10(1):85–92. https://doi.org/10.1093/scan/nsu026.

    Article  PubMed  Google Scholar 

  • Freynhagen R, Backonja M, Schug S, Lyndon G, Parsons B, Watt S, Behar R. Pregabalin for the treatment of drug and alcohol withdrawal symptoms: a comprehensive review. CNS Drugs. 2016;30(12):1191–200. Review

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Foulds JA, Sellman JD, Mulder RT. Antidepressant therapy for depressed patients with an alcohol use disorder. Aust N Z J Psychiatry. 2016;50(3):199–200. https://doi.org/10.1177/0004867415609427.

    Article  PubMed  Google Scholar 

  • Garbutt JC, West SL, Carey TS, Lohr KN, Crews FT. Pharmacological treatment of alcohol dependence: a review of the evidence. J Am Med Assoc. 1999;281:1318–25.

    Article  CAS  Google Scholar 

  • Garbutt JC, Kranzler HR, O’Malley SS, Gastfriend DR, Pettinati HM, Silverman BL, Loewy JW, Ehrich EW, Vivitrex Study Group. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA. 2005;293(13):1617–25.

    Article  CAS  PubMed  Google Scholar 

  • Gessa GL, Serra S, Vacca G, Carai MA, Colombo G. Suppressing effect of the cannabinoid CB1 receptor antagonist, SR147778, on alcohol intake and motivational properties of alcohol in alcohol-preferring sP rats. Alcohol Alcohol. 2005;40(1):46–53.

    Article  CAS  PubMed  Google Scholar 

  • Glassman AH, Stetner F, Walsh BT, Raizman PS, Fleiss JL, Cooper TB, Covey LS. Heavy smokers, smoking cessation, and clonidine: results of a double-blind, randomized trial. JAMA. 1988;259:2863–6.

    Article  CAS  PubMed  Google Scholar 

  • Goh ET, Morgan MY. Review article: pharmacotherapy for alcohol dependence—the why, the what and the wherefore. Aliment Pharmacol Ther. 2017;45(7):865–82. https://doi.org/10.1111/apt.13965.

    Article  CAS  PubMed  Google Scholar 

  • Gómez-Coronado N, Walker AJ, Berk M, Dodd S. Current and emerging pharmacotherapies for cessation of tobacco smoking. Pharmacotherapy. 2018a;38(2):235–58. https://doi.org/10.1002/phar.2073.

    Article  PubMed  Google Scholar 

  • Gómez-Coronado N, Walker AJ, Berk M, Dodd S. Current and emerging pharmacotherapies for cessation of tobacco smoking. Pharmacotherapy. 2018b;38(2):235–58. Review

    Article  PubMed  Google Scholar 

  • Gonzales DH, Rennard SI, Billing CB, Reeves KR. A pooled analysis of varenicline, an alpha4beta2 nicotinic receptor partial agonist versus bupropion for smoking cessation. Presented at Society for Research on Nicotine and Toobacco; 2006.

    Google Scholar 

  • Guglielmo R, Martinotti G, Quatrale M, Ioime L, Kadilli I, Di Nicola M, Janiri L. Topiramate in alcohol use disorders: review and update. CNS Drugs. 2015;29(5):383–95. https://doi.org/10.1007/s40263-015-0244-0.

    Article  CAS  PubMed  Google Scholar 

  • Hall FS, Der-Avakian A, Gould TJ, Markou A, Shoaib M, Young JW. Negative affective states and cognitive impairments in nicotine dependence. Neurosci Biobehav Rev. 2015;58:168–85. https://doi.org/10.1016/j.neubiorev.2015.06.004.

    Article  PubMed  PubMed Central  Google Scholar 

  • Hall SM, Reus VI, Munoz RF, Sees KL, Humfleet G, Hartz DT, Frederick S, Triffleman E. Nortriptyline and cognitive-behavioral therapy in the treatment of cigarette smoking. Arch Gen Psychiatry. 1998;55:683–9.

    Article  CAS  PubMed  Google Scholar 

  • Harro J, Oreland L. The role of MAO in personality and drug use. Prog Neuro-Psychopharmacol Biol Psychiatry. 2016;69:101–11.

    Article  CAS  Google Scholar 

  • Hashimoto JG, Wiren KM. Neurotoxic consequences of chronic alcohol withdrawal: expression profiling reveals importance of gender over withdrawal severity. Neuropsychopharmacology. 2008;33(5):1084–96.

    Article  CAS  PubMed  Google Scholar 

  • Heilig M, Koob GF. A key role for corticotropin-releasing factor in alcohol dependence. Trends Neurosci. 2007;30(8):399–406.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Heinz A, Mann K, Weinberger DR, Goldman D. Serotonergic dysfunction, negative mood states, and response to alcohol. Alcohol Clin Exp Res. 2001;25:487–95.

    Article  CAS  PubMed  Google Scholar 

  • Henningfield JE, Fant RV, Gopalan L. Non-nicotine medications for smoking cessation. J Respir Dis. 1998;19:33–42.

    Google Scholar 

  • Henningfield JE, Fant RV, Buchhalter AR, Stitzer ML. Pharmacotherapy for nicotine dependence. CA Cancer J Clin. 2005;55:281–99.

    Article  PubMed  Google Scholar 

  • Hernández-Martínez C, Voltas Moreso N, Ribot Serra B, Arija Val V, Escribano Macías J, Canals SJ. Effects of prenatal nicotineexposure on infant language development: a cohort follow up study. Matern Child Health J. 2017;21(4):734–44. https://doi.org/10.1007/s10995-016-2158-y.

    Article  PubMed  Google Scholar 

  • Hernandez-Avila CA, Song C, Kuo L, Tennen H, Armeli S, Kranzler HR. Targeted versus daily naltrexone: secondary analysis of effects on average daily drinking. Alcohol Clin Exp Res. 2006;30(5):860–5.

    Article  PubMed  Google Scholar 

  • Hesselbrock VM, Hesselbrock MN. Are there empirically supported and clinically useful subtypes of alcohol dependence? Addiction. 2006;101(1):97–103.

    Article  PubMed  Google Scholar 

  • Hill EM, Stoltenberg SF, Bullard KH, Li S, Zucker RA, Burmeister M. Antisocial alcoholism and serotonin-related polymorphisms: association tests. Psychiatr Genet. 2002;12(3):143–53.

    Article  PubMed  Google Scholar 

  • Holm KJ, Spencer CM. Bupropion: a review of its use in the management of smoking cessation. Drugs. 2000;59:1007–24.

    Article  CAS  PubMed  Google Scholar 

  • Hölter SM, Danysz W, Spanagel R. Evidence for alcohol anti-craving properties of memantine. Eur J Pharmacol. 1996;314(3):R1–2.

    Article  PubMed  Google Scholar 

  • Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2004;(4):CD000031.

    Google Scholar 

  • Hughes JR, Stead LF, Hartmann-Boyce J, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2014;(8):CD000031.

    Google Scholar 

  • Hurt RT, Ebbert JO, Croghan IT, Schroeder DR, Hurt RD, Hays JT. Varenicline for tobacco-dependence treatment in alcohol-dependent smokers: a randomized controlled trial. Drug Alcohol Depend. 2018;184:12–7. https://doi.org/10.1016/j.drugalcdep.2017.11.017.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hwang BH, Wang GM, Wong DT, Lumeng L, Li TK. Norepinephrine uptake sites in the locus coeruleus of rat lines selectively bred for high and low alcohol preference: a quantitative autoradiographic binding study using [3H]-tomoxetine. Alcohol Clin Exp Res. 2000;24(5):588–94.

    Article  CAS  PubMed  Google Scholar 

  • Ipser JC, Wilson D, Akindipe TO, Sager C, Stein DJ. Pharmacotherapy for anxiety and comorbid alcohol use disorders. Cochrane Database Syst Rev. 2015;1:CD007505.

    PubMed  Google Scholar 

  • Jackson KJ, Muldoon PP, De Biasi M, Damaj MI. New mechanisms and perspectives in nicotine withdrawal in. Neuropharmacology. 2015;96:223–34.

    Article  CAS  PubMed  Google Scholar 

  • Jakovljevic M, Jovanovic M, Rancic N, Vyssoki B, Djordjevic N. LAT software induced savings on medical costs of alcohol addicts’ care: results from a matched pairs case control study. PLoS One. 2014;7:9.

    Google Scholar 

  • Javors M, Tiouririne M, Prihoda T. Platelet serotonin uptake is higher in early onset than in late-onset alcoholics. Alcohol Alcohol. 2000;35:390–3.

    Article  CAS  PubMed  Google Scholar 

  • Jeanblanc J, Coune F, Botia B, Naassila M. Brain-derived neurotrophic factor mediates the suppression of alcohol self-administration by memantine. Addict Biol. 2014;19(5):758–69. https://doi.org/10.1111/adb.12039.

    Article  CAS  PubMed  Google Scholar 

  • Joca SR, Ferreira FR, Guimaraes FS. Modulation of stress consequences by hippocampal monoaminergic, glutamatergic and nitrergic neurotransmitter systems. Stress. 2007;10(3):227–49.

    Article  CAS  PubMed  Google Scholar 

  • Johnson BA. Serotonergic agents and alcoholism treatment: rebirth of the subtype concept—a hypothesis. Alcohol Clin Exp Res. 2000;24:1597–601.

    CAS  PubMed  Google Scholar 

  • Johnson BA, Ait-Daoud N. Neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Psychopharmacology. 2000;149:327–44.

    Article  CAS  PubMed  Google Scholar 

  • Johnson BA, Roache JD, Javors MA, DiClemente CC, Cloninger CR, Prihoda TJ, Bordnick PS, Ait-Daoud N, Hensler J. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: a randomized controlled trial. J Am Med Assoc. 2000a;284:963–71.

    Article  CAS  Google Scholar 

  • Johnson BA, Ait-Daoud N, Bowden CL, DiClemente CC, Roache JD, Lawson K, Javors MA, Ma JZ. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet. 2003a;361(9370):1677–85.

    Article  CAS  PubMed  Google Scholar 

  • Johnson BA, Ruiz P, Galanter M. Handbook of clinical alcoholism treatment. Philadelphia, PA: Lippincott Williams & Wilkins; 2003b.

    Google Scholar 

  • Johnson BA. Role of the serotonergic system in the neurobiology of alcoholism: implications for treatment. CNS Drugs. 2004a;18(15):1105–18.

    Article  CAS  PubMed  Google Scholar 

  • Johnson BA. Progress in the development of topiramate for treating alcohol dependence: from a hypothesis to a proof-of-concept study. Alcohol Clin Exp Res. 2004b;28(8):1137–44.

    Article  CAS  PubMed  Google Scholar 

  • Johnson BA, Ait-Daoud N, Akhtar FZ, Ma JZ. Oral topiramate reduces the consequences of drinking and improves the quality of life of alcohol-dependent individuals: a randomized controlled trial. Arch Gen Psychiatry. 2004;61(9):905–12.

    Article  CAS  PubMed  Google Scholar 

  • Johnson BA, Ait-Daoud N, Akhtar FZ, Javors MA. Use of oral topiramate to promote smoking abstinence among alcohol-dependent smokers: a randomized controlled trial. Arch Intern Med. 2005;165(14):1600–5.

    Article  CAS  PubMed  Google Scholar 

  • Johnson BA, Ait-Daoud N, Prihoda TJ. Combining ondansetron and naltrexone effectively treats biologically predisposed alcoholics: from hypotheses to preliminary clinical evidence. Alcohol Clin Exp Res. 2000b;24(5):737–42.

    Article  CAS  PubMed  Google Scholar 

  • Johnson BA, Rosenthal N, Capece JA, Wiegand F, Mao L, Beyers K, McKay A, Ait-Daoud N, Addolorato G, Anton RF, Ciraulo DA, Kranzler HR, Mann K, O'Malley SS, Swift RM, Topiramate for Alcoholism Advisory Board; Topiramate for Alcoholism Study Group. Improvement of physical health and quality of life of alcohol-dependent individuals with topiramate treatment: US multisite randomized controlled trial. Arch Intern Med. 2008;168(11):1188–99.

    Article  CAS  PubMed  Google Scholar 

  • Johnson BA. Toward Rational, Evidence Based, and Clinically Relevant Measures to Determine Improvement Following Tratment for Alcohol Use Disorder. Alc. Clin Exp Res. 2017;41(4):703–7.

    Article  Google Scholar 

  • Jordan CJ, Xi ZX. Discovery and development of varenicline for smoking cessation. Expert Opin Drug Discov. 2018;13(7):671–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR, Smith SS, Muramoto ML, Daughton DM, Doan K, Fiore MC, Baker TB. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med. 1999;340:685–91.

    Article  CAS  PubMed  Google Scholar 

  • Kalivas P, Volkow N. The neural basis of addiction: a pathology of motivation and choice. Am J Psychiatry. 2005;162:8.

    Article  Google Scholar 

  • Kampman KM, Pettinati HM, Lynch KG, Whittingham T, Macfadden W, Dackis C, Tirado C, Oslin DW, Sparkman T, O’Brien CP. A double blind, placebo controlled pilot trial of Quetiapine fort he treatment of Type A and Type B alcoholism. J Clin Psychopharmacol. 2007;27(4):344–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kiefer F, Helwig H, Tarnaske T, Otte C, Jahn H, Wiedemann K. Pharmacological relapse prevention of alcoholism: clinical predictors of outcome. Eur Addict Res. 2005a;11:83–91.

    Article  PubMed  Google Scholar 

  • Kiefer F, Jahn H, Wiedemann K. A neuroendocrinological hypothesis on gender effects of naltrexone in relapse prevention treatment. Pharmacopsychiatry. 2005b;38(4):184–6.

    Article  CAS  PubMed  Google Scholar 

  • Klemperer EM, Hughes JR, Naud S. Study characteristics influence the efficacy of substance abuse treatments: a meta-analysis of medications for alcohol use disorder. Drug Alcohol Depend. 2018;190:229–34.

    Article  PubMed  Google Scholar 

  • Klesges RC, Meyers AW, Klesges LM, La Vasque ME. Smoking, body weight, and their effects on smoking behaviour: a comprehensive review of the literature. Psychol Bull. 1989;106:204–30.

    Article  CAS  PubMed  Google Scholar 

  • Klesges RC, Winders SE, Meyers AW, Eck LH, Ward KD, Hultquist CM, Ray JW, Shadish WR. How much weight gain occurs following smoking cessation? A comparison of weight gain using both continuous and point prevalence abstinence. J Consult Clin Psychol. 1997;65:286–91.

    Article  CAS  PubMed  Google Scholar 

  • Koob GF. Neurocircuitry of alcohol addiction: synthesis from animal models. Handb Clin Neurol. 2014;125:33–54.

    Article  PubMed  Google Scholar 

  • Kotlyar M, Lindgren BR, Vuchetich JP, Le C, Mills AM, Amiot E, Hatsukami DK. Timing of nicotine lozenge administration to minimize trigger induced craving and withdrawal symptoms. Addict Behav. 2017;71:18–24.

    Article  PubMed  PubMed Central  Google Scholar 

  • Koppi S, Eberhardt G, Haller R, König P. Calcium-channel-blocking agent in the treatment of acute alcohol withdrawal—caroverine versus meprobamate in a randomized doubleblind study. Neuropsychobiology. 1987;17(1–2):49–52.

    Article  CAS  PubMed  Google Scholar 

  • Kosten TR, George TP, Kosten TA. The potential of dopamine agonists in drug addiction. Expert Opin Investig Drugs. 2002;11(4):491–9. Review

    Article  CAS  PubMed  Google Scholar 

  • Kranzler HR, Burleson JA, Brown J, Babor TF. Fluoxetine treatment seems to reduce the beneficial effects of cognitive behavioral therapy in type B alcoholics. Alcohol Clin Exp Res. 1996;20:1534–41.

    Article  CAS  PubMed  Google Scholar 

  • Kranzler HR, Burleson JA, DelBoca FK, Baqbor TF, Korner P, Brown L, Bohn MJ. Buspirone treatment of anxiousa alcoholics. A placebo-controlled trial. Arch Gen Pdychiat. 1994;51:720–31.

    Article  CAS  Google Scholar 

  • Kranzler HR, Lappalainen J, Nellissery M, Gelernter J. Association study of alcoholism subtypes with a functional promoter polymorphism in the serotonin transporter protein gene. Alcohol Clin Exp Res. 2002;26(9):1330–5.

    Article  CAS  PubMed  Google Scholar 

  • Krishnan-Sarin S, O’Malley SS, Franco N, Cavallo DA, Morean M, Shi J, Pittman B, Krystal JH. N-methyl-D-aspartate receptor antagonism has differential effects on alcohol craving and drinking in heavy drinkers. Alcohol Clin Exp Res. 2015;39(2):300–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Krupitsky EM, Rudenko AA, Burakov AM, Slavina TY, Grinenko AA, Pittman B, Gueorguieva R, Petrakis IL, Zvartau EE, Krystal JH. Antiglutamatergic strategies for ethanol detoxification: comparison with placebo and diazepam. Alcohol Clin Exp Res. 2007;31(4):604–11.

    CAS  PubMed  Google Scholar 

  • Krystal JH, Webb E, Cooney NL, Kranzler HR, Charney DS. Specifity of ethanollike effects elicited by serotonergic and noradrenergic mechanisms. Arch Gen Psychiatry. 1994;51:898–911.

    Article  CAS  PubMed  Google Scholar 

  • Laaksonen E, Koski-Jännes A, Salaspuro M, Ahtinen H, Alho H. A randomized, multicentre, open-label, comparative trial of disulfiram, naltrexone and acamprosate in the treatment of alcohol dependence. Alcohol Alcohol. 2008;43(1):53–61.

    Article  CAS  PubMed  Google Scholar 

  • Le Foll B, Melihan-Cheinin P, Rostoker G, Lagrue G; Working Group of AFSSAPS. Smoking cessation guidelines: evidence-based recommendations of the French Health Products Safety Agency. Eur Psychiatry. 2005;20(5–6):431–41.

    Google Scholar 

  • Lee HY, Li SP, Park MS, Bahk YH, Chung BC, Kim MO. Ethanol’s effect on intracellular signal pathways in prenatal rat cortical neurons is GABAB1 dependent. Synapse. 2007;61(8):622–8.

    Article  CAS  PubMed  Google Scholar 

  • Léger M, Brunet M, Le Roux G, Lerolle N, Boels D. Baclofen self-poisoning in the era of changing indication: multicentric reports to a French poison control centre. Alcohol Alcohol. 2017;52(6):665–70. https://doi.org/10.1093/alcalc/agx072.

    Article  CAS  PubMed  Google Scholar 

  • Leone MA, Vigna-Taglianti F, Avanzi G, Brambilla R, Faggiano F. Gamma-hydroxyburate ( GHB) for treatment of alcohol withdrawal and prevention of relapses. Cochrane Database Syst Rev. 2010;(2):CD006266. Review

    Google Scholar 

  • LeMarquand D, Pihl RO, Benkelfat C. Serotonin and alcohol intake, abuse, and dependence: clinical evidence. Biol Psychiatry. 1994;36(5):326–37.

    Article  CAS  PubMed  Google Scholar 

  • Lerman C, Niaura R, Collins BN, Wileyto P, Audrain-McGovern J, Pinto A, Hawk L, Epstein LH. Effect of bupropion on depression symptoms in a smoking cessation clinical trial. Psychol Addict Behav. 2004;18:362–6.

    Article  PubMed  Google Scholar 

  • Lesch OM. Chronischer Alkoholismus—Typen und ihr Verlauf—eine Langzeitstudie. Thieme Copythek. Georg Thieme Verlag: Stuttgart, New York; 1985.

    Google Scholar 

  • Lesch OM, Lesch E, Dietzel M, Musalek M, Walter H, Zeiler K. Chronischer Alkoholismus—Alkoholfolgekrankheiten—Faktoren, die die Lebenserwartung beeinflussen. Sammelband der Van Swieten Tagung. Verlag der österreichischen Ärztekammer; 1986a. pp. 92–98.

    Google Scholar 

  • Lesch OM, Musalek M, Wessely P, Zeiler K. Neurologische und psychiatrische Akutmaßnahmen, Abschnitt Psychiatrie. Wien: Facultas Universitätsverlag; 1986b. p. 160–3.

    Google Scholar 

  • Lesch OM, Walter H. Subtypes of alcoholism and their role in therapy. Alcohol Alcohol Suppl. 1996;1:63–7.

    Article  Google Scholar 

  • Lesch OM, Riegler A, Gutierrez K, Hertling I, Ramskogler K, Semler B, Zoghlami A, Benda N, Walter H. The European Acamprosate trials: conclusions for research and therapy. J Biomed Sci. 2001;8(1):89–95.

    Article  CAS  PubMed  Google Scholar 

  • Lesch OM, Dvorak A, Hertling I, Klingler A, Kunze M, Ramskogler K, Saletu-Zylharz G, Schoberberger R, Walter H. The Austrian multicentre study on smoking: subgroups of nicotine dependence and their craving. Neuropsychobiology. 2004;50:78–88.

    Article  PubMed  Google Scholar 

  • Lesch OM. Raucherentwöhnung – Tipps zur Prävention und Therapie in der Praxis. Bremen: Uni-Med Verlag; 2007.

    Google Scholar 

  • Linnoila M, Virkkunen M, Scheinin M, Nuutila A, Rimon R, Goodwin FK. Low cerebrospinal fluid 5-hydroxyindolacetic concentration differentiates impulsive from nonimpulsive violent behavoir. Life Science. 1983;33:2609–14.

    Article  CAS  Google Scholar 

  • Litten RZ, Allen JP. Advances in the development of medications for alcoholism treatment. Psychopharmacology. 1998;139:20–33.

    Article  CAS  PubMed  Google Scholar 

  • Longo LP, Campbell T, Hubatch S. Divalproex sodium (Depakote) for alcohol withdrawal and relapse prevention. J Addict Dis. 2002;21(2):55–64.

    Article  PubMed  Google Scholar 

  • Lopez-Moreno JA, Gonzalez-Cuevas G, Navarro M. The CB1 cannabinoid receptor antagonist rimonabant chronically prevents the nicotine-induced relapse to alcohol. Neurobiol Dis. 2007;25(2):274–83.

    Article  CAS  PubMed  Google Scholar 

  • Lotfullina N, Khazipov R. Ethanol and the developing brain: inhibition of neuronal activity and neuroapoptosis. Neuroscientist. 2018;24(2):130–41.

    Article  CAS  PubMed  Google Scholar 

  • Lovinger DM. Serotonin’s role in alcohol’s effect on the brain. Alcohol Health Res World. 1997;21(2):114–20.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Ma JZ, Ait-Daoud N, Johnson BA. Topiramate reduces the harm of excessive drinking: implications for public health and primary care. Addiction. 2006;101(11):1561–8.

    Article  PubMed  Google Scholar 

  • Mann K, Bladström A, Torup L, Gual A, van den Brinck W. Extending the treatment options in alcohol dependence:a randomized controlled study o fas needed nalmefene. Biol Psychiatry. 2013;73:706–13.

    Article  CAS  PubMed  Google Scholar 

  • Malcolm R, Anton RF, Randall CL, Johnston A, Brady K, Thevos A. A placebo-controlled trial of buspirone in anxious inpatient alcoholics. Alcohol Clin Exp Res. 1992;16:1007–13.

    Article  CAS  PubMed  Google Scholar 

  • Malec E, Malec T, Gagne MA, Dongier M. Buspirone in the treatment of alcohol dependence: a placebo controlled trial. Alcohol Clin Exp Res. 1996a;20:307–12.

    Article  CAS  PubMed  Google Scholar 

  • Malec TS, Malec EA, Dongier M. Efficacy of buspirone in alcohol dependence: a review. Alcohol Clin Exp Res. 1996b;20:853–8.

    Article  CAS  PubMed  Google Scholar 

  • Mann K, Lehert P, Morgan MY. The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis. Alcohol Clin Exp Res. 2004;28(1):51–63.

    Article  PubMed  Google Scholar 

  • Marcinkiewcz CA, Lowery-Gionta EG, Kash TL. Serotonin’s complex role in alcoholism: implications for treatment and future research. Alcohol Clin Exp Res. 2016;40(6):1192–201.

    Article  CAS  PubMed  Google Scholar 

  • Markou A, Kosten TR, Koob GF. Neurobiological similarities in depression and drug dependence: a self-medication hypothesis. Neuropsychopharmacology. 1998;18:135–74.

    Article  CAS  PubMed  Google Scholar 

  • Mascia MP, Maiya R, Borghese CM, Lobo IA, Hara K, Yamakura T, Gong DH, Beckstead MJ. Does acetaldehyde mediate ethanol action in the central nervous system? Alcohol Clin Exp Res. 2001;25(11):1570–5.

    Google Scholar 

  • Mason BJ, Quello S, Shadan F. Gabapentin for the treatment of alcohol use disorder. Expert Opin Investig Drugs. 2018;27(1):113–24.

    Article  CAS  PubMed  Google Scholar 

  • Mason BJ, Kocsis JH, Ritvo EC, Cutler RB. A double-blind, placebo-controlled trial of desipramine for primary alcohol dependence stratified on the presence or absence of major depression. JAMA. 1996;13(275/10):761–7.

    Article  Google Scholar 

  • Mason BJ. Acamprosate, alcoholism, and abstinence. J Clin Psychiatry. 2015;76(2):e224–5.

    Article  PubMed  Google Scholar 

  • Mc Grath PJ, Nunes EV, Stewart JW, Goldman D, Agosti V, Ocepek-Welikson K, Quitkin FM. Imipramine treatment of alcoholics with primary depression: a placebo-controlled clinical trial. Arch Gen Psychiatry. 1996;53(3):232–40.

    Article  CAS  Google Scholar 

  • McLaughlin I, Dani JA, De Biasi M. Nicotine withdrawal. Curr Top Behav Neurosci. 2015;24:99–123.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Miller WR and Rollnick S. Motivational interviewing: Preparing people for change (2nd edition) New York: Guilford Press. 2002.

    Google Scholar 

  • Minozzi S, Saulle R, Rösner S. Baclofen for alcohol use disorder. Cochrane Database Syst Rev. 2018;11:CD012557.

    PubMed  Google Scholar 

  • Mueller TI, Stout RL, Rudden S, Brown RA, Gordon A, Solomon DA, Recupero PR. A double-blind, placebo-controlled pilot study of carbamazepine for the treatment of alcohol dependence. Alcohol Clin Exp Res. 1997;21(1):86–92.

    Article  CAS  PubMed  Google Scholar 

  • Murphy JK, Edwards NB, Downs AD, Ackerman BJ, Rosenthal TL. Effects of doxepin on withdrawal symptoms in smoking cessation. Am J Psychiatry. 1990;147:1353–7.

    Article  CAS  PubMed  Google Scholar 

  • Musshoff F, Lachenmeier DW, Schmidt P, Dettmeyer R, Madea B. Systematic regional study of dopamine, norsalsolinol, and (R/S)-salsolinol levels in human brain areas of alcoholics. Alcohol Clin Exp Res. 2005;29(1):46–52.

    Article  CAS  PubMed  Google Scholar 

  • Mutschler J, Grosshans M, Soyka M, Rösner S. Current findings and mechanisms of action of disulfiram in the treatment of alcohol dependence. Pharmacopsychiatry. 2016;49(4):137–41. https://doi.org/10.1055/s-0042-103592.

    Article  CAS  PubMed  Google Scholar 

  • Nagy J. Renaissance of NMDA receptor antagonists: do they have a role in the pharmacotherapy for alcoholism? Drugs. 2004;7(4):339–50.

    CAS  Google Scholar 

  • Nakamura-Palacios EM, de Almeida Benevides MC, da Penha Zago-Gomes M, de Oliveira RW, de Vasconcellos VF, de Castro LN, da Silva MC, Ramos PA, Fregni F. Auditory event-related potentials (P3) and cognitive changes induced by frontal direct current stimulation in alcoholics according to Lesch alcoholism typology. Int J Neuropsychopharmacol. 2012;15(5):601–16.

    Article  PubMed  Google Scholar 

  • Naranjo CA, Knoke DM. The role of selective serotonin reuptake inhibitors in reducing alcohol consumption. J Clin Psychiatry. 2001;62(20):18–25.

    CAS  PubMed  Google Scholar 

  • National Institute for Clinical Excellence. Guidance on the use of nicotine replacement therapy (NRT) and bupropion for smoking cessation. London, England: National Institute for Clinical Excellence; 2004. Reference No. N0082

    Google Scholar 

  • Nava F, Premi S, Manzato E, Lucchini A. Comparing treatments of alcoholism on craving and biochemical measures of alcohol consumptions in. J Psychoactive Drugs. 2006;38(3):211–7.

    Article  PubMed  Google Scholar 

  • Nguyen SA, Malcolm R, Middaugh LD. Topiramate reduces ethanol consumption by C57BL/6 mice. Synapse. 2007;61(3):150–6.

    Article  CAS  PubMed  Google Scholar 

  • Nimmerrichter A, Walter H, Guttierez-Lobos K, Lesch OM. Double-blind controlled trial of GHB and Clomethiazole in the treatment of alcohol withdrawal. Alcohol Alcohol. 2002;37(1):67–73.

    Article  CAS  PubMed  Google Scholar 

  • Nutt DJ, Lingford-Hughes A, Erritzoe D, Stokes PR. The dopamine theory of addiction: 40 years of highs and lows. Nat Rev Neurosci. 2015;16(5):305–12.

    Article  CAS  PubMed  Google Scholar 

  • O’Brien CP. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence. Curr Psychiatry Rep. 2005;7(5):327–8.

    Article  PubMed  Google Scholar 

  • O’Malley SS, Cooney JL, Krishnan-Sarin S, Dubin JA, McKee SA, Cooney NL, Blakeslee A, Meandzija B, Romano-Dahlgard D, Wu R, Makuch R, Jatlow P. A controlled trial of naltrexone augmentation of nicotine replacement therapy for smoking cessation. Arch Intern Med. 2006;166(6):667–74.

    Article  PubMed  Google Scholar 

  • O’Malley SS, Sinha R, Grilo CM, Capone C, Farren CK, McKee SA, Rounsaville BJ, Wu R. Naltrexone and cognitive behavioral coping skills therapy for the treatment of alcohol drinking and eating disorder features in alcohol-dependent women: a randomized controlled trial. Alcohol Clin Exp Res. 2007;31(4):625–34.

    PubMed  Google Scholar 

  • Oncken C, Gonzales D, Nides M, Rennard S, Watsky E, Billing CB, Anziano R, Reeves K. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for Smoking Cessation. Arch Intern Med. 2006;166:1571–7.

    Article  CAS  PubMed  Google Scholar 

  • Oncken C, Arias AJ, Feinn R, Litt M, Covault J, Sofuoglu M, Kranzler HR. Topiramate for smoking cessation: a randomized, placebo-controlled pilot study. Nicotine Tob Res. 2014;16(3):288–96.

    Article  CAS  PubMed  Google Scholar 

  • Ooteman W, Koeter MW, Verheul R, Schippers GM, van den Brink W. The effect of naltrexone and acamprosate on cue-induced craving, autonomic nervous system and neuroendocrine reactions to alcohol-related cues in alcoholics. Eur Neuropsychopharmacol. 2007;17(8):558–66.

    Article  CAS  PubMed  Google Scholar 

  • Opalach C, Romaszko J, Jaracz M, Kuchta R, Borkowska A, Buciński A. Coping styles and alcohol dependence among homeless people. PLoS One. 2016;11(9):e0162381.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Pakri Mohamed RM, Kumar J, Ahmad SU, Mohamed IN. Noverl pharmacotherapeutic approaches in treatment of alcohol addiction. Curr Drug Targets. 2018;19(12):1378–90.

    Article  CAS  PubMed  Google Scholar 

  • Palpacuer C, Duprez R, Huneau A, Locher C, Boussageon R, Laviolle B, Naudet F. Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate. Addiction. 2018;113(2):220–37. https://doi.org/10.1111/add.13974.

    Article  PubMed  Google Scholar 

  • Paulus DJ, Manning K, Hogan JBD, Zvolensky MJ. The role of anxiety sensitivity in the relation between anxious arousal and cannabis and alcohol use problems among low-income inner city racial/ethnic minorities. J Anxiety Disord. 2017;48:87–94.

    Article  PubMed  Google Scholar 

  • Perney P, Lehert P. Insomnia in alcohol-dependent patients: prevalence, risk factors and acamprosate effect: an individual patient data meta-analysis. Alcohol Alcohol. 2018;53(5):611–8. https://doi.org/10.1093/alcalc/agy013.

    Article  CAS  PubMed  Google Scholar 

  • Petrakis IL, O’Malley S, Rounsaville B, Poling J, McHugh-Strong C, Krystal JH, VA Naltrexone Study Collaboration Group. Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia. Psychopharmacology. 2004;172(3):291–7.

    Article  CAS  PubMed  Google Scholar 

  • Pettinati HM, Volpicelli JR, Kranzler HR, Luck G, Rukstalis MR, Cnaan A. Sertraline treatment for alcohol dependence: interactive effects of medication and alcoholic subtype. Alcohol Clin Exp Res. 2000;24:1041–9.

    Article  CAS  PubMed  Google Scholar 

  • Pettinati HM. The use of selective serotonin reuptake inhibitors in treating alcoholic subtypes. J Clin Psychiatry. 2001;62(20):26–31.

    CAS  PubMed  Google Scholar 

  • Pettinati HM, Kranzler HR, Madaras J. The status of serotonin-selective pharmacotherapy in the treatment of alcohol dependence. Recent Dev Alcohol. 2003;16:247–62.

    PubMed  Google Scholar 

  • Pettinati HM. Antidepressant treatment of co-occurring depression and alcohol dependence. Biol Psychiatry. 2004;56(10):785–92. Review

    Article  CAS  PubMed  Google Scholar 

  • Pettinati HM, O’Brien CP, Rabinowitz AR, Wortman SP, Oslin DW, Kampman KM, Dackis CA. The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking. J Clin Psychopharmacol. 2006;26(6):610–25.

    Article  CAS  PubMed  Google Scholar 

  • Pettinati HM, Oslin DW, KIampmann KM, Dundon WD, Xie H. Gallis TL, Dackis CA, O’Brien CP. A Double-Blind, Placebo-Controlled Trial Combining Sertraline and Naltrexone for Treating Co-Occurring Depression and Alcohol Dependence. Am J Psychiatry. 2010;167:668–75.

    Google Scholar 

  • Pierce M, Sutterland A, Beraha E, Morley K, van den Brink W. Efficacy, tolerability and safety of low dose and high dose baclofen in the treatment of alcohol dependence: a systematic review and meta analysis. Eur Neuropsychopharmacol. 2018;26:1959.

    Google Scholar 

  • Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J, RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA. 2006;295(/7):761–75.

    Article  CAS  PubMed  Google Scholar 

  • Pittman B, Gueorguieva R, Krupitsky E, Rudenko AA, Flannery BA, Krystal JH. Multidimensionality of the Alcohol withdrawal symptom checklist: a factor analysis of the alcohol withdrawal symptom checklist and CIWA-Ar. Alcohol Clin Exp Res. 2007;31(4):612–8.

    PubMed  Google Scholar 

  • Pombo S, Luísa Figueira M, Walter H, Lesch O. Motivational factors and negative affectivity as predictors of alcohol craving. Psychiatry Res. 2016;243:53–60.

    Article  PubMed  Google Scholar 

  • Prochaska JO, DiClemente CC. Stages and processes of self-change of smoking: toward an integrative model of change. J Consult CDlin Psychol. 1983;51(3):390–5.

    Article  CAS  Google Scholar 

  • Prochazka AV, Weaver MJ, Keller RT, Fryer GE, Licari PA, Lofaso D. A randomized trial of nortriptyline for smoking cessation. Arch Intern Med. 1998;158:2035–9.

    Article  CAS  PubMed  Google Scholar 

  • Reddemann L. Psychodynamisch imaginative traumatherapie: PITT®—Das manual. Ein resilienzorientierter Ansatz in der Psychotraumatologie. Verlagm, Leben lernen; 2014

    Google Scholar 

  • Reid RD, Quinlan B, Riley DL, Pipe AL. Smoking cessation: lessons learned from clinical trial evidence. Curr Opin Cardiol. 2007;22(4):280–5.

    Article  PubMed  Google Scholar 

  • Reis AM, Quintal C, Lourenço Ó. Killing two birds with one stone? Association between tobacco and alcohol consumption. Public Health. 2018;154:136–43. https://doi.org/10.1016/j.puhe.2017.10.019. Epub 2017 Dec 22. Review

    Article  CAS  PubMed  Google Scholar 

  • Reynaud M, Aubin HJ, Trinquet F, Zakine B, Dano C, Dematteis M, Trojak B, Paille F, Detilleux M. A randomized placebo-controlled study of high-dose baclofen in alcohol-dependent patients—the ALPADIR study. Alcohol Alcohol. 2017;52:439–46.

    Article  CAS  PubMed  Google Scholar 

  • Robinson JD, Cinciripini PM, Karam-Hage M, Aubin HJ, Dale LC, Niaura R, Anthenelli RM, STRATUS Group. Pooled analysis of three randomized, double-blind, placebo controlled trials with rimonabant for smoking cessation. Addict Biol. 2018;23(1):291–303. https://doi.org/10.1111/adb.12508.

    Article  CAS  PubMed  Google Scholar 

  • Roberts W, Shi JM, Tetrault JM, McKee SA. Effects of varenicline alone and in combination with low-dose naltrexone on alcohol-primed smoking in heavy-drinking tobacco users: a preliminary laboratory study. J Addict Med. 2018;12(3):227–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Robinson TE, Berridge KC. The neural basis of drug craving-an incentive-sensitization theory of addiction. Brain Res Brain Res Rev. 1993;18:247–91.

    Article  CAS  PubMed  Google Scholar 

  • Rodda LN, Beyer J, Gerostamoulos D, Drummer OH. Alcohol congener analysis and the source of alcohol: a review. Forensic Sci Med Pathol. 2013;9(2):194–207.

    Article  PubMed  Google Scholar 

  • Rodríguez-Cano R, López-Durán A, Martínez-Vispo C, Martínez Ú, Fernández Del Río E, Becoña E. Hazardous alcohol drinking as predictor of smoking relapse (3-, 6-, and 12-months follow-up) by gender. J Subst Abus Treat. 2016;71:79–84. https://doi.org/10.1016/j.jsat.2016.09.005.

    Article  Google Scholar 

  • Rollema H, Coe JW, Chambers LK, Hurst RS, Stahl SM, Williams KE. Rationale, pharmacology and clinical efficacy of partial agonists of alpha(4)beta(2) nACh receptors for smoking cessation. Trends Pharamcol Sci. 2007;28(7):316–25.

    Article  CAS  Google Scholar 

  • Rommelspacher H, May T, Dufeu P, Schmidt LG. Longitudinal observations of monoamine oxidase B in alcoholics: differentiation of marker characteristics. Alcohol Clin Exp Res. 1994;18:1322–9.

    Article  CAS  PubMed  Google Scholar 

  • Rommelspacher H. Rauchen aus der Sicht der Hirnforschung. In: Lesch OM, editor. Raucherentwöhnung—Tipps zur Prävention und Therapie in der Praxis. Bremen: Uni-Med Verlag; 2007.

    Google Scholar 

  • Rohsenow DJ, Howland J. The role of beverage congeners in hangover and other residual effects of alcohol intoxication: a review. Curr Drug Abuse Rev. 2010;3(2):76–9. Review

    Article  CAS  PubMed  Google Scholar 

  • Rose JE, Behm FM. Combination varenicline/bupropion treatment benefits highly dependent smokers in an adaptive smoking cessation paradigm. Nicotine Tob Res. 2017;19(8):999–1002.

    CAS  PubMed  Google Scholar 

  • Sällström Baum S, Hill R, Rommelspacher H. Norharmaninduced changes of extracellular concentrations of dopamine in the nucleus accumbens of rats. Life Sci. 1995;56:1715–20.

    Article  Google Scholar 

  • Sällström Baum S, Hill R, Rommelspacher H. Harman induced changes of extracellular concentrations of neurotransmitters in the nucleus accumbens of rats. Eur J Pharmacol. 1996;314:75–82.

    Article  Google Scholar 

  • Samochowiec A, Chec M, Kopaczeweska E, Samochowiec J, Lesch O, Grochans E, Jasiewicz A, Bienkowski P, Lukasz K, Grzywacz A. Monamine oxidase a promoter variable number of tandem repeats (MAOA-uVNTR) in alcoholics according to Lesch typology. Int J Envir Res Public Health. 2015;12(3):3317–27.

    Article  CAS  Google Scholar 

  • Scharf D, Shiffman S. Are there gender differences in smoking cessation, with and without bupropion? Pooled-and meta-analyses of clinical trials of bupropion SR. Addiction. 2004;99:1462–9.

    Article  PubMed  Google Scholar 

  • Scherrer B, Guiraud J, Poulnais R, Raffaillac-desfosse Q. Predictive factors of placebo response in the treatment of alcohol dependence. Eur Neuropsychopharmacol (Draft Manuscript). 2019

    Google Scholar 

  • Schlam TR, Cook JW, Baker TB, Hayes-Birchler T, Bolt DM, Smith SS, Fiore MC, Piper ME. Can we increase smokers' adherence to nicotine replacement therapy and does this help them quit? Psychopharmacology. 2018;235(7):2065–75. https://doi.org/10.1007/s00213-018-4903-y.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Schoonover K, Burton MC, Larson SA, Cha SS, Lapid MI. Depression and alcohol withdrawal syndrome: is antidepressant therapy associated with lower rates of hospital readmission? Ir J Med Sci. 2016;185(3):573–9. https://doi.org/10.1007/s11845-015-1304-7.

    Article  CAS  PubMed  Google Scholar 

  • Schnoll RA, Lerman C. Current and emerging pharmacotherapies for treating tobacco dependence. Expert Opin Emerg Drugs. 2006;11(3):429–44.

    Article  CAS  PubMed  Google Scholar 

  • Schuckit M, Smith T, PiersonJ, Danko G, Beltran IA. Relationships among the level of response to alcohol and the number of alcoholic relatives in predicting alcohol-related outcomes. Alc. Clin Exp Res. 2006;30(8):1308–14.

    Google Scholar 

  • Scott-Goodwin AC, Puerto M, Moreno I. Toxic effects of prenatal exposure to alcohol, tobacco and other drugs. Reprod Toxicol. 2016;61:120–30.

    Article  CAS  PubMed  Google Scholar 

  • Secades-Villa R, González-Roz A, García-Pérez Á, Becoña E. Psychological, pharmacological, and combined smoking cessation interventions for smokers with current depression: a systematic review and meta-analysis. PLoS One. 2017;12(12):e0188849.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Shiffman S, Gnys M, Richards TJ, Paty JA, Hickcox M, Kassel JD. Temptations to smoke after quitting: a comparison of lapsers and maintainers. Health Psychol. 1996;15:455–61.

    Article  CAS  PubMed  Google Scholar 

  • Shiffman S, Johnston JA, Khayrallah M, Elash CA, Gwaltney CJ, Paty JA, Gnys M, Evoniuk G, DeVeaugh-Geiss J. The effect of bupropion on nicotine craving and withdrawal. Psychopharmacology. 2000;148:33–40.

    Article  CAS  PubMed  Google Scholar 

  • Shoaib M, Buhidma Y. Why are antidepressant drugs effective smoking cessation aids? Curr Neuropharmacol. 2018;16:426–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Skala K, Caputo F, Mirijello A, Vassallo G, Antonelli M, Ferrulli A, Walter H, Lesch O, Addolorato G. Sodium oxybate in the treatment of alcohol dependence: from the alcohol withdrawal syndrome to the alcohol relapse prevention. Expert Opin Pharmacother. 2014;15(2):245–57. Review

    Article  CAS  PubMed  Google Scholar 

  • Simiand J, Keane M, KeanePE SP. SR 141716, a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset. Behav Pharmacol. 1998;9(2):179–81.

    CAS  PubMed  Google Scholar 

  • Simon JA, Duncan C, Carmody TP, Hudes ES. Bupropion for smoking cessation: a randomized trial. Arch Intern Med. 2004;164(16):1797–803.

    Article  CAS  PubMed  Google Scholar 

  • Sinclair JD. Evidence about the use of naltrexone and for different ways of using it in the treatment of alcoholism. Alcohol Alcohol. 2001;36(1):2–10.

    Article  CAS  PubMed  Google Scholar 

  • Soyka M, Koller G, Schmidt P, Lesch OM, Leweke M, Fehr C, Gann H, Mann KF, ACTOL Study Investigators. Cannabinoid receptor 1 blocker rimonabant (SR 141716) for treatment of alcohol dependence: results from a placebo-controlled, double-blind trial. J Clin Psychopharmacol. 2008;28(3):317–24.

    Article  CAS  PubMed  Google Scholar 

  • Soyka M, Müller CA. Pharmacotherapy of alcoholism—an update on approved and off-label medications. Expert Opin Pharmacother. 2017;18(12):1187–99.

    Article  CAS  PubMed  Google Scholar 

  • Soyka M, Friede M, Schnitker J. Comparing nalmefene and naltrexone in alcohol dependence: are there any differences? Results from an indirect meta-analysis. Pharmacopsychiatry. 2016a;49(2):66–75.

    Article  CAS  PubMed  Google Scholar 

  • Soyka M, Friede M, Schnitker J. Comparing nalmefene and naltrexone in alcohol dependence: are there any differences? Results from an indirect meta-analysis. Pharmacopsychiatry. 2016b;49(2):66–75.

    Article  CAS  PubMed  Google Scholar 

  • Spanagel R, Zieglgansberger W. Anti-craving compounds for ethanol: new pharmacological tools to study addictive processes. Trends Pharmacol Sci. 1997;18(2):54–9.

    Article  CAS  PubMed  Google Scholar 

  • Spanagel R, Hölter SM. Long-term-alcohol self-administration with repeated alcohol deprivation phases; an animal model of alcoholism? Alcohol Alcohol. 1999;34(2):231–43.

    Article  CAS  PubMed  Google Scholar 

  • Sprung R, Bonte W, Lesch OM. Methanol, Ein bisher verkannter Bestandteil aller alkoholischen Getränke; Eine neue biochemische Annäherung an das Problem des chronischen Alkoholismus. Wien Klin Wochenschr. 1988;100(9):282–8.

    CAS  PubMed  Google Scholar 

  • Starosta AM, Leeman R, Volpicelli MD. The BRENDA model: integrating psychosocial treatment and pharmacotherapy for the treatment of alcohol use disorders. J Psychiat Pract. 2006;12:80–9.

    Article  Google Scholar 

  • Stead L, Lancaster T. Interventions to reduce harm from continued tobacco use. Cochrane Database Syst Rev. 2007;(3):CD005231.

    Google Scholar 

  • Steensland P, Simms JA, Holgate J, Richards JK, Bartlett SE. Varenicline, an {alpha}4{beta}2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking. Proc Natl Acad Sci U S A. 2007;104(30):12518–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Stolz D, Scherr A, Seiffert B, Kuster M, Meyer A, Fagerström KO, Tamm M. Predictors of success for smoking cessation at the workingplace: a longitudinal study in. Respiration. 2014;87:18–25.

    Article  PubMed  Google Scholar 

  • Stuppaeck CH, Barnas C, Falk M, Guenther V, Hummer M, Oberbauer H, Pycha R, Whitworth AB, Fleischhacker WW. Assessment of the alcohol withdrawal syndrome-validity and reliability of the translated and modified Clinical Institute Withdrawal Assessment for Alcohol scale (CIWA-A). Addiction. 1994;89(10):1287–92.

    Article  CAS  PubMed  Google Scholar 

  • Sullivan EV, Pfefferbaum A. Neurocircuitry in alcoholism: a substrate of disruption and repair. Psychopharmacology. 2005;180(4):583–94.

    Article  CAS  PubMed  Google Scholar 

  • Sullivan J, Baenziger JC, Wagner DL, Rauscher FP, Nurnberger JI, Holmes S. Platelet MAO in subtypes of alcoholism. Biol Psychiatry. 1990;27:911–22.

    Article  CAS  PubMed  Google Scholar 

  • Swann AS, Johnson BA, Cloninger CR, Chen YR. Alcoholism and serotonin: relationships of plasma tryptophan availibility to course of illness and clinical features. Psychopharmacology. 1999;143:380–4.

    Article  CAS  PubMed  Google Scholar 

  • Sweeney CT, Fant RV, Fagerström KO, McGovern JF, Henningfield JE. Combination nicotine replacement therapy for smoking cessation: rationale, efficacy and tolerability. CNS Drugs. 2001;15:453–67.

    Article  CAS  PubMed  Google Scholar 

  • Tabakoff B, Hoffmann PL. Neurochemical effects of alcohol. In: Frances RJ, Miller SI, editors. Clinical textbook of addictive disorders. New York: Guilford Press; 1991. p. 501–25.

    Google Scholar 

  • Taylor GMJ, Taylor AE, Thomas KH, Jones T, Martin RM, Munafò MR, Windmeijer F, Davies NM. The effectiveness of varenicline versus nicotine replacement therapy on long-term smoking cessation in primary care: a prospective cohort study of electronic medical records. Int J Epidemiol. 2017;46(6):1948–57.

    Article  PubMed  PubMed Central  Google Scholar 

  • Tellenbach H. Melancholie. Berlin, Heidelberg. 4. Auflage: Springer Verlag; 1983.

    Book  Google Scholar 

  • Tiesler CM, Heinrich J. Prenatal nicotine exposure and child behavioural problems. Eur Child Adolesc Psychiatry. 2014 Oct;23(10):913–29. https://doi.org/10.1007/s00787-014-0615-y.

    Article  PubMed  PubMed Central  Google Scholar 

  • Tonnesen P, Paoletti P, Gustavsson G, Russell MA, Saracci R, Gulsvik A, Rijcken B, Sawe U. Higher dosage nicotine patches increase one-year smoking cessation rates: results from the European CEASE trial. Collaborative European Anti-Smoking Evaluation. European Respiratory Society. Eur Respir J. 1999;13:238–46.

    Article  CAS  PubMed  Google Scholar 

  • Tonstad S, Tonnesen P, Hajek P, Williams KE, Billing CB, Reeves KR. Effect of maintenance therapy with varenicline on smoking cessation—a randomized controlled trial. JAMA. 2006;296(1):64–71.

    Article  CAS  PubMed  Google Scholar 

  • Tschabitscher P, Homaier I, Lichtenschopf A, Groman E. Varenicline—pharmacological therapy of tobacco dependence. Wien Med Wochenschr. 2009;159(1–2):17–23. https://doi.org/10.1007/s10354-008-0636-6.

    Article  PubMed  Google Scholar 

  • UNODC and WHO (Commission on Narcotic Drugs). International Standards for the Treatment of Drug Use. 2016

    Google Scholar 

  • US Department of Health and Human Services. Management of Nicotine Addiction. Reducing Tobacco Use: a report of the surgeon General. Atlanta, GA: Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health. 2000.

    Google Scholar 

  • Van Praag HM, Brown SL, Asnis GM, Kahn RS, Korn ML, Harkavy-Friedman JM, Wetzler S. Beyond serotonin: a multiaminergic perspective on abnormal behavior. In: Brown SL, van Praag HM, editors. The role of serotonin in psychiatric disorders. New York: Brunner/Mazel; 1991. p. 302–32.

    Google Scholar 

  • Vengeliene V, Olevska A, Spanagel R. Long-lasting effect of NMDA receptor antagonist memantine on ethanol-cue association and relapse. J Neurochem. 2015;135(6):1080–5.

    Article  CAS  PubMed  Google Scholar 

  • Verheul R, Lehert P, Geerlings PJ, Koeter MW, van den Brink W. (2005) Predictors of acamprosate efficacy: results from a pooled analysis of seven European trials including 1485 alcoholdependent patients. Psychopharmacology 1782–3:167–173.

    Google Scholar 

  • Virkkunen M, Rawlings R, Tokola R, Poland RE, Guidotti A, Nemeroff C, Bissette G, Kalogeras K, Karonen SL, Linnoila M. CSF biochemistries, glucose metabolism, and diurnal a ctivity rhythms in alcoholic, violent offenders, fire setters, and healthy volunteers. Arch Gen Psychiatry. 1994;51:20–7.

    Article  CAS  PubMed  Google Scholar 

  • Virkkunen M, Eggert M, Rawlings R, Linnoila M. A prospective follow-up study of alcoholic violent offenders and fire setters. Arch Gen Psychiatry. 1996;53:523–9.

    Article  CAS  PubMed  Google Scholar 

  • Virkkunen M, Linnoila M. Serotonin on early-onset alcoholism. Recent Dev Alcohol. 1997;13:173–89.

    CAS  PubMed  Google Scholar 

  • Vogeler T, McClain C, Evoy KE. Combination bupropion SR and varenicline for smoking cessation: a systematic review. Am J Drug Alcohol Abuse. 2016;42(2):129–39. https://doi.org/10.3109/00952990.2015.1117480.

    Article  PubMed  Google Scholar 

  • Volkow N, Koob G, McLellan T. Neurobiologic advances from the brain disease model of addiction. N Engl J Med. 2016;374:4.

    Article  CAS  Google Scholar 

  • Volpicelli JR, Alterman AI, Hayashida M, O’Brien CP. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry. 1992;49(11):876–80.

    Article  CAS  PubMed  Google Scholar 

  • Volpicelli JR, Rhines KC, Rhines JS, Volpicelli LA, Alterman AI, O’Brien CP. Naltrexone and alcohol dependence. Role of subject compliance. Arch Gen Psychiatry. 1997;54(8):737–42.

    Article  CAS  PubMed  Google Scholar 

  • Vyssoki B, Steindl-Munda P, Ferenci P, Walter H, Höfer P, Blüml V, Friedrich F, Kogoj D, Lesch OM. Comparison of alcohol-dependent patients at a gastroenterological and a psychiatric ward according to the Lesch alcoholism typology: implications for treatment. Alcohol Alcohol. 2010;45(6):534–40.

    Article  PubMed  Google Scholar 

  • Wang J, Rao Y, Houser DE. An experimental analysis of acquired impulsecontrol among adult humans intolerant to alcohol. Proc Natl Acad Sci U S A. 2017;114(6):1299–304.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Walter H. Alkohol. In: Revenstorf D, Peter B, editors. Hypnose in Psychotherapie, Psychosomatik und Medizin. Manual für die Praxis. Kapitel 28. Heidelberg: Springer Verlag; 2015. (3. Auflage).

    Google Scholar 

  • Walter H, Ramskogler K, Semler B, Lesch OM, Platz W. Dopamine and alcohol relapse: D1 and D2 antagonists increase relapse rates in animal studies and in clinical trials. J Biomed Sci. 2001;8:83–8.

    Article  CAS  PubMed  Google Scholar 

  • Walter H, Rösner L. Nicht immer ist die Abstinenz das Ziel. Psychopraxis. Neuropraxis. 2018;21(6):272–275. https://doi.org/10.1007/s00739-018-0529-4. http://link.springer.com/article/10.1007/s00739-018-0529-4

  • Weinshenker D, Schroeder JP. There and back again: a tale of norepinephrine and drug addiction. Neuropsychopharmacology. 2007;32(7):1433–51.

    Article  CAS  PubMed  Google Scholar 

  • Wiener CD, Moreira FP, Zago A, Souza LM, Branco JC, Oliveira JF, Silva RAD, Portela LV, Lara DR, Jansen K, Oses JP. Mood disorder, anxiety, and suicide risk among subjects with alcohol abuse and/or dependence: a population-based study. Braz J Psychiatry. 2018;40(1):1–5.

    Article  PubMed  Google Scholar 

  • Whitworth AB, Fischer F, Lesch OM, Nimmerrichter A, Oberbauer H, Platz T, Potgieter A, Walter H, Fleischhacker WW. Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet. 1996;347(9013):1438–42.

    Article  CAS  PubMed  Google Scholar 

  • Widiger TA, Frances AJ, Picus HA, First MB, Ross R, Davis W. DSM-IV sourcebook, vol. 1. Washington, DC: American Psychiatric Association; 1994.

    Google Scholar 

  • Wieck HH. Lehrbuch für Psychiatrie. Stuttgart: Schattauer; 1967.

    Google Scholar 

  • Wiesbeck GA, Weijers HG, Lesch OM, Glaser T, Toennes PJ, Boening J. Flupenthixol decanoate and relapse prevention in alcoholics: results from a placebo-controlled study. Alcohol Alcohol. 2001;36(4):329–34.

    Article  CAS  PubMed  Google Scholar 

  • Williams KE, Reeves KR, Billing CB Jr, Pennington AM, Gong J. A double-blind study evaluating the long-term safety of varenicline for smoking cessation. Curr Med Res Opin. 2007;23(4):793–801.

    Article  CAS  PubMed  Google Scholar 

  • World Health Organization. Policy recommendations for smoking cessation and treatment of tobacco dependence. Geneva: World Health Organization; 2003.

    Google Scholar 

  • Xie S, Furjanic MA, Ferrara JJ, McAndrew NR, Ardino EL, Ngondara A, Bernstein Y, Thomas KJ, Kim E, Walker JM, Nagar S, Ward SJ, Raffa RB. The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism—or inverse agonism—as potential obesity treatment and other therapeutic use. J Clin Pharm Ther. 2007;32(3):209–31.

    Article  CAS  PubMed  Google Scholar 

  • Yates GL, MacKenzie R, Pennbridge J, Cohen E. A risk profile comparison of runaway and non-runaway youth. Am J Public Health. 1988;78:820–1.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Yingst JM, Veldheer S, Hrabovsky S, Sciamanna C, Foulds J. Reasons for non-adherence to nicotine patch therapy during the first month of a quit attempt. Int J Clin Pract. 2015;69(8):883–8. https://doi.org/10.1111/ijcp.12644.

    Article  CAS  PubMed  Google Scholar 

  • Yuanyuan J, Junyan Z, Cuola D, Jingjing C, Yuhui S, Dan X, Wei D, Yongsheng Z. Memantine attenuated alcohol withdrawal-induced anxiety-like behaviors through down-regulating NR1-CaMKII-ERK signaling pathway. Neurosci Lett. 2018;686:133–9.

    Article  PubMed  CAS  Google Scholar 

  • Zago-Gomes Mda P, Nakamura-Palacios EM. Cognitive components of frontal lobe function in alcoholics classified according to Lesch’s typology. Alcohol Alcohol. 2009;44(5):449–57.

    Article  PubMed  Google Scholar 

  • Zierler-Brown S, Kyle JA. Oral varenicline for smoking cessation. Ann Pharmacother. 2007;41:95–9.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Division of Social Psychiatry, Medical University Vienna, Department of Psychiatry and Psychotherapy, Vienna, Austria

    Otto-Michael Lesch & Henriette Walter

  2. Caritas der Erzdiözese Wien, Vienna, Austria

    Christian Wetschka

  3. Department of Psychiatry, University of Connecticut Health Center, Farmington, CT, USA

    Michie N. Hesselbrock & Victor Hesselbrock

  4. Neuroscience Department, Hospital de Santa Maria, Lisboa, Portugal

    Samuel Pombo

Authors
  1. Otto-Michael Lesch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Henriette Walter
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christian Wetschka
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michie N. Hesselbrock
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Victor Hesselbrock
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Samuel Pombo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Otto-Michael Lesch .

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Lesch, OM., Walter, H., Wetschka, C., Hesselbrock, M.N., Hesselbrock, V., Pombo, S. (2020). Therapeutic Strategies in Alcohol and Tobacco Addiction. In: Alcohol and Tobacco. Springer, Cham. https://doi.org/10.1007/978-3-030-41941-7_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-41941-7_9

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-41940-0

  • Online ISBN: 978-3-030-41941-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation